Analysis of WCID-cIEF Spectrogram of Recombinant Interleukin-15 Fusion Protein
SHI Xin-chang, LI Xiang, YU Lei, GUO Ying, LI Yong-hong, PEI De-ning*, RAO Chun-ming*
Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing 100050, China
Abstract：OBJECTIVE To analyze the glycosylated chains of recombinant interleukin-15 fusion protein using capillary isoelectric focusing-whole column imaging detection (WCID-cIEF) spectrograms. METHODS Using established corresponding mathematical models and the least square method, the WCID-cIEF spectrograms of whole protein, de-salicylic-acid protein and de-N-glycosylation-chain protein were analyzed. Among the mathematical models, the interval-1-peak model was selected. And according to the model, the relationship between isoform peak-areas and isoelectric points was listed. RESULTS The rationality of the interval-1-peak model was confirmed and a series of basic data was obtained according to the model as follows:the apparent m value of the protein was 25.53 reference(R), the apparent n value of the protein was 28.83R, the apparent m value of sialic acid was 0.86 (0.855) R, the apparent n value was 0.12 (0.119) R, the apparent n value of N-acetylglucosamine (undifferentiated from N-acetylgalactosamine) was 0.06(0.061) R, and the apparent m value of formed carboxyl after N-chain removal was 0.19 (0.186) R. Some information of protein sugar composition was also obtained: the sialylation degree was about 1.83 mol·mol-1, the percentage of prototype protein was about 8.3%, the percentage of single N-glycosated modification protein was about 19.8%, the percentage of double N-glycosated modification protein was about 28.4%, the percentage of triple N-glycosated modification protein was about 23.7%, and the percentage of O-glycosated modification (with sialic acid) protein was about 19.8%. The main sugar types should be G0 (F), G1 (F), G2 (F), G1A1 (F), and G2A1 (F). CONCLUSION The structure of sugar chain is complex, but it also has some repeatability and regularity. We hope that through this study, the glycoprotein sugar chain can be quickly outlined, the understanding of glycoprotein and the study of protein interaction can be improved.
MORTIER E, QUEMENER A, VUSIO P, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins[J].J Biol Chem, 2006,281(3):1612-1619.
[2]
STONE J D, CHERVIN A S, SCHREIBER H, et al. Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor[J]. Biotechnol Prog, 2012,28(6):1588-1597.
[3]
LI X, YU L, GUO Y, et al. Charge heterogeneity evaluation of IL-15 fusion protein by capillary isolectric focusing-whole column imaging detection[J]. Chin New Drugs J(中国新药杂志),2018,27(19):2232-2237.
[4]
JING J, FANG T, YUN C, et al. Site-specific qualitative and quantitative analysis of N-and O-glycoforms in recombinant human erythropoietin[J]. Anal Bioanal Chem, 2014,406(25):6265-6274.
[5]
LUIZ H A, CRAWFORD J, GASCON P, et al. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short-and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia[J]. Crit Rev Oncol Hematol, 2018,129:79-90.
[6]
LI X,SHI X C,FAN W H, et al. Estimation of the degree of salivary acidification of recombinant-human-erythropoietin(rhEPO) [J]. Chin Pharm J(中国药学杂志), 2018,53(19):1682-1686.
[7]
LI X,SHI X C,FAN W H, et al. Proportion and in vivo specific activity of recombinant human erythropoietin isoforms[J]. Chin J Biol(中国生物制品学杂志),2018,31(8):841-845.
[8]
JESSICA S C, NATHAN J O,SUSAN M L, et al. Recent advances in the analysis of therapeutic proteins by capillary and microchip electrophoresis[J]. Anal Methods, 2014,6(15):5427-5449.
[9]
SCHAUER R C. Metabolism, and biological functions of sialic acids[J]. Adv Carbohydr Chem Biochem, 1982,40:131-234.
[10]
CABEZAS J A. Some questions and suggestions on the type references of the official nomenclature (IUB) for sialidase(s) and endosialidase[J]. Biochem J, 1991,278 (Pt 1):311-312.
[11]
SONGSRIROTE K, LI Z, ASHFORD D, et al. Development and application of mass spectrometric methods for the analysis of progranulin N-glycosylation[J]. J Proteomics, 2010,73(8):1479-1490.
[12]
SEGU Z M, HUSSEIN A, NOVOTNY M V, et al. Assigning N-glycosylation sites of glycoproteins using LC-MS/MS in conjunction with endo-M/exoglycosidase mixture[J]. J Proteome Res, 2010,9(7):3598-3607.
[13]
STAWISKI E W, MANDEL-GUTFREUND Y, LOWENTHAL A C, et al. Progress in predicting protein function from structure:unique features of O-glycosidases[J]. Pac Symp Biocomput, 2002:637-648.
[14]
RUHAAK L R, MIYANOTO S, KELLY K, et al. N-glycan profiling of dried blood spots[J]. Anal Chem, 2012,84(1):396-402.
[15]
CHANG K H, BAEK N I, YANG J M, et al. Expression and characterization of recombinant beta-secretase from trichoplusia ni BTI Tn5B1-4 cells transformed with cDNAs encoding human beta1,4-galactosyltransferase and Gal beta1,4-GlcNAc alpha 2,6-sialytransferase[J]. Protein Expr Purif, 2005,44(2):87-93.
2020, Vol. 55 
